Stockscreener 앱 받기
242.60
0.70%
-1.71
시장 영업 전:
244.98
2.38
+0.98%
Axsome Therapeutics Inc 주식(AXSM)의 최신 뉴스
Axsome therapeutics CEO Herriot Tabuteau sells $11.9 million in shares - Investing.com UK
Form 4 Axsome Therapeutics Inc For: 1 July By Investing.com - Investing.com Canada
Axsome therapeutics CEO Herriot Tabuteau sells $11.9 million in shares By Investing.com - Investing.com Canada
Axsome Therapeutics (AXSM) CEO sells 49,666 exercised shares under 10b5-1 plan - Stock Titan
Form 144 Axsome Therapeutics For: 1 July By Investing.com - Investing.com Canada
49,666-share sale notice for AXSM (NASDAQ: AXSM) via cashless exercise - Stock Titan
Why Axsome Stock Has Doubled In Nine Months - Yahoo! Finance Canada
AXSM Stock Is Rising Today After Wall Street’s Positive Stance Despite Mixed Q1 – What's Behind The Optimism? - Stocktwits
Pictet Asset Management Holding SA Sells 20,080 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Sleep Apnea Market Expected to Experience Accelerated Growth and Market Evolution by 2034 – DelveInsight | Apnimed, Eli Lilly, Incannex Healthcare, Axsome Therapeutics, Jazz Pharma, Bioprojet - Barchart.com
Axsome Therapeutics, Inc.(NasdaqGM: AXSM) dropped from Russell 2000 Index - marketscreener.com
Axsome Therapeutics, Inc.(NasdaqGM: AXSM) added to Russell Midcap Growth Benchmark - marketscreener.com
Axsome Therapeutics, Inc.(NasdaqGM:AXSM) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Axsome Therapeutics, Inc. (AXSM) Stock Analysis: Strong Buy Ratings Signal Potential Upside In Biotech Sector - DirectorsTalk Interviews
Axsome Therapeutics, Inc.(NasdaqGM: AXSM) added to Russell 1000 Growth Benchmark - marketscreener.com
Axsome Therapeutics, Inc.(NasdaqGM: AXSM) dropped from Russell 2000 Dynamic Index - marketscreener.com
AXSM Stock In Spotlight Ahead Of Key FDA Verdict On Alzheimer’s Drug This Week - Stocktwits
Price to sales forward of Axsome Therapeutics, Inc. – NASDAQ:AXSM - TradingView
Price to sales forward of Axsome Therapeutics, Inc. – LSX:A2AA7B - TradingView
Axsome doses first patient in phase 3 ADHD trial By Investing.com - Investing.com Australia
Price to earnings forward of Axsome Therapeutics, Inc. – NASDAQ:AXSM - TradingView
Price to earnings forward of Axsome Therapeutics, Inc. – LSX:A2AA7B - TradingView
Axsome Therapeutics (AXSM) Initiates FOCUS-3 Trial for ADHD Trea - GuruFocus
Axsome Therapeutics doses first patient in FOCUS-3 phase 3 ADHD trial - grafa.com
Axsome doses first patient in phase 3 ADHD trial - Investing.com UK
Axsome starts Phase 3 trial of solriamfetol for ADHD in adolescents, aiming to improve treatment options. - Pluang
Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD) - The Manila Times
Axsome Therapeutics, Inc. Actuals & Estimates (NASDAQ:AXSM) - TradingView
Axsome Therapeutics, Inc. Actuals & Estimates (FWB:19X) - TradingView
Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock - Stocktwits
Price to book forward of Axsome Therapeutics, Inc. – NASDAQ:AXSM - TradingView
Price to book forward of Axsome Therapeutics, Inc. – LSE:0HKF - TradingView
Enterprise value to EBITDA forward of Axsome Therapeutics, Inc. – LSE:0HKF - TradingView
Enterprise value to revenue forward of Axsome Therapeutics, Inc. – NASDAQ:AXSM - TradingView
Assenagon Asset Management S.A. Grows Stock Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Price to earnings forward of Axsome Therapeutics, Inc. – LSE:0HKF - TradingView
Understanding the Setup: (AXSM) and Scalable Risk - Stock Traders Daily
Axsome Therapeutics Inc (AXSM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Definium's LSD-based depression pill delivers strong late-stage results, shares surge - Reuters
Axsome Therapeutics, Inc. (AXSM) Stock Analysis: A Biotech Leader with 57.4% Revenue Growth and Strong Buy Ratings - DirectorsTalk Interviews
Axsome Therapeutics Inc (AXSM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Enterprise value of Axsome Therapeutics, Inc. – XETR:19X - TradingView
Virtu Financial LLC Invests $2.84 Million in Axsome Therapeutics, Inc. $AXSM - MarketBeat
12,955 Shares in Axsome Therapeutics, Inc. $AXSM Purchased by Seven Fleet Capital Management LP - MarketBeat
Axsome Therapeutics Inc (AXSM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Axsome Therapeutics Inc (AXSM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Axsome Therapeutics Inc (AXSM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
AXSM Stock Clocks Best Day In About 4 Months On FDA Greenlight For Alzheimer’s Drug - Stocktwits
Axsome Therapeutics (NASDAQ:AXSM) Hits New 1-Year High on Analyst Upgrade - MarketBeat
Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month - Yahoo Finance
Cormorant Asset Management LP Sells 25,000 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
BVF Inc. IL Sells 441,000 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome joins Alzheimer’s awareness push as 7M Americans live with disease - Stock Titan
Axsome Therapeutics Inc (AXSM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Axsome Therapeutics Inc (AXSM) Institutional Confidence - TradingKey
AXSM Maintains Buy Rating by TD Cowen -- Price Target Raised to $300 - GuruFocus
TD Cowen raises Axsome Therapeutics price target on Auvelity growth - Investing.com
TD Cowen raises Axsome Therapeutics price target on Auvelity growth By Investing.com - Investing.com South Africa
Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $300.00 at TD Cowen - MarketBeat
Hypercharge Announces Issuance of Equity Grants - GlobeNewswire Inc.
Cynosure Group LLC Sells 4,369 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
0.05%
0.74%
자본화:
|
볼륨(24시간):